Related Experiment Video

Updated: Mar 28, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1

Zengyan Liu1, Guoqiang Zhang2, Wenzheng Yu3

  • 1Department of Hematology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, Shandong 250012, China; Department of Hematology, Hospital Affiliated to Binzhou Medical University, 661 Second Huanghe Street, Binzhou 256603, China.

Biochemical and Biophysical Research Communications
|December 19, 2015
PubMed

Insights

MicroRNAs (miRNAs) are key regulators in cancer. This study shows miR-186 acts as a tumor suppressor in multiple myeloma (MM) by inhibiting cell growth and targeting Jagged1, offering a potential therapeutic target for MM.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNAs (miRNAs) are small noncoding RNAs regulating gene expression.
  • miRNAs play a role in hematologic malignancies.
  • The function of miRNAs in multiple myeloma (MM) pathogenesis is not fully understood.

Purpose of the Study:

  • To investigate the role of miR-186 in multiple myeloma (MM).
  • To identify the molecular targets and mechanisms of miR-186 in MM.

Main Methods:

  • Assessed miR-186 expression in MM cell lines and patient samples.
  • Performed in vitro and in vivo functional assays upon ectopic miR-186 expression.
  • Identified Jagged1 as a direct target of miR-186 by 3'-UTR analysis.

Main Results:

  • miR-186 was found to be downregulated in MM.
  • Overexpression of miR-186 inhibited MM cell proliferation and induced G0/G1 cell cycle arrest.
  • miR-186 directly targets Jagged1, and Jagged1 overexpression rescues MM cells from miR-186-mediated growth inhibition.

Conclusions:

  • miR-186 functions as a tumor suppressor in multiple myeloma (MM).
  • miR-186 warrants further investigation as a potential therapeutic target for MM.
Keywords:
Jagged1Multiple myelomaProliferationmiR-186

More Related Videos

Stimulation of Notch Signaling in Mouse Osteoclast Precursors08:01

Stimulation of Notch Signaling in Mouse Osteoclast Precursors

Published on: February 28, 2017

8.4K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.9K